Mind Medicine (MindMed) (OTCMKTS:MMEDF) Trading Up 2.2% – Time to Buy?

Shares of Mind Medicine (MindMed) Inc. (OTCMKTS:MMEDF) were up 2.2% on Friday . The company traded as high as $39.78 and last traded at $38.68. Approximately 1,729,902 shares were traded during mid-day trading, a decline of 49% from the average session volume of 3,376,665 shares. The stock had previously closed at $37.85.

Mind Medicine (MindMed) Trading Up 2.2%

The company has a 50-day moving average price of $42.48 and a 200-day moving average price of $30.81.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) is a clinical-stage biotechnology company focused on developing innovative therapies derived from psychedelic compounds to address mental health disorders and addiction. The company’s research pipeline includes programs based on LSD, psilocybin and 18-methoxycoronaridine (18-MC), targeting conditions such as anxiety disorders, attention-deficit/hyperactivity disorder (ADHD) and opioid dependence. MindMed seeks to build a portfolio of drug candidates that combine pharmacological efficacy with optimized dosing regimens and delivery methods.

Founded in 2019 and headquartered in New York City, MindMed operates research facilities in North America and Europe, collaborating with academic institutions and medical centers to advance its clinical trials.